Use cases
Global health solutions
Use cases
Anti-D Hyperimmune
Anti-D Hyperimmune is a blood product made of plasma used to prevent Rh sensitisation in Rh-negative individuals. It is a blood product containing antibodies against the RhD antigen, which is found on the surface of red blood cells.
Haemolytic Disease of the Fetus and New Born (HDFN or Rh disease)
Rh-negative pregnant women may receive Anti-D Hyperimmune to prevent Rh sensitisation if their baby is Rh-positive. This is important because Rh sensitisation during pregnancy can lead to hemolytic disease of the newborn, a condition that can cause serious health problems for the baby.
TAM
The Anti-D Immunoglobulin market was estimated to be approximately USD 3.5 billion in 2024, and with a CAGR of ~8%, could reach USD $5.5 billion by 2033.
Rabies Immunoglobulin (RIG)
Rabies Immunoglobulin (RIG) is a blood product derived from plasma and is used to prevent rabies infection after exposure to the rabies virus. It contains antibodies that help fight the virus and provide immediate protection.
Rabies Infection
Once Rabies virus infects the central nervous system and clinical symptoms appear, it becomes 100% fatal. But Rabies deaths are preventable with prompt use of RIG. RIG provides immediate passive immune protection by giving the body antibodies until it can produce its own.
TAM
The Rabies Hyperimmune globulin market was valued up to USD 650 million in 2023. It is forecasted to grow to USD 1.33 billion by 2033, with a CAGR of 7%.
Tetanus Hyperimmune Globulin (TIG)
Tetanus Hyperimmune Globulin (TIG) is a blood product made from plasma that contains antibodies against the tetanus bacteria. The antibodies in TIG help to neutralise the toxin produced by the bacteria and prevent the disease from developing.
Tetanus
TIG is recommended for severe tetanus infections and for treating serious wounds, especially those contaminated with dirt, feces, soil, or saliva. It is also used for injuries from warfare, crushing, burns, or frostbite and should ideally be given within 24 hours but can still be effective if administered up to 48 hours after the injury.
TAM
TIG has a current market value more than USD 200 million. With its unique clinical role in the management of Tetanus, it is forecasted to grow at 5-7% – projecting a 2033 market value in excess of USD 400 million.
Cytomegalovirus Hyperimmune Globulin (CMV IG)
Cytomegalovirus Hyperimmune Globulin (CMV IG) is a blood product made from plasma that contains antibodies against the cytomegalovirus (CMV). The antibodies in CMV IG help neutralize the virus and lessen the severity of the infection.
Cytomegalovirus
Cytomegalovirus can cause serious problems in pregnant women and immune-compromised individuals, such as those undergoing transplants. Cytomegalovirus Immunoglobulin (CMV IG) is used to provide passive immunity, helping to prevent complications like organ rejection, pneumonia, or transmission of CMV to unborn babies.
TAM
The current CMV HIg market is approx. USD 475 million. The category will grow to USD 830 by 2030, a CAGR of almost 8%.
Hepatitis B Hyperimmune Globulin (HBIG)
Hepatitis B Hyperimmune Globulin (HBIG) is a blood product derived from plasma rich in antibodies that provide immediate, passive protection against the hepatitis B virus (HBV).
Hepatitis B (Hep B)
Hepatitis B Immunoglobulin (HBIG) is used to provide immediate protection against hepatitis B in specific situations. It is commonly given after liver transplants, exposure to infected blood, or sexual transmission, especially for healthcare workers or other at-risk individuals. HBIG is also used for newborns whose mothers test positive for hepatitis B to reduce the risk of transmission.
TAM
The global Hep B Ig market is currently worth up to USD 1.7 billion and is projected to grow to approx. USD 2.8 billion by 2033 – a CAGR of ~7.5%.
Varicella Zoster Virus Hyperimmune Globulin (VZV IG)
Varicella Zoster Virus Hyperimmune Globulin (VZV IG) is a blood product made from plasma containing high levels of antibodies against the varicella-zoster virus, which causes chickenpox and shingles.
Varicella Zoster Virus
Varicella Zoster Virus Hyperimmune Globulin (VZV IG) is used to prevent or reduce the severity of varicella (chickenpox) and shingles in individuals at high risk, such as newborns, pregnant women, and people with weakened immune systems. It is typically given after exposure to the varicella-zoster virus to provide immediate passive immunity.
TAM
The global Varicella Zoster Ig market is was approx. USD 170 million in 2024. This is expected to grow at a CAGR of 3.5% to over USD 200 million by 203.
Global health solutions
Other Derived Products
Factor VIII
Read more
Factor VIII is a crucial protein in the blood clotting process, also known as a clotting factor. It plays a key role in the coagulation cascade, which helps the blood to clot and stop bleeding when an injury occurs.
Hemophilia A
To treat hemophilia A, Factor VIII replacement therapy is often used, where synthetic or donated Factor VIII is introduced into the patient’s bloodstream to help their blood clot properly.
TAM
The global hemophilia market, where Hemophilia A constitutes a large portion, is expected to grow from USD 5.66 billion in 2022 to over USD 9.2 billion by 2030, at a compound annual growth rate (CAGR) of 6.3%.
Factor IX
Read more
Factor IX (FIX) is a vitamin K-dependent protein produced in the liver and is part of the coagulation cascade, a series of steps the body uses to form blood clots. It is activated through complex pathways when there’s an injury to a blood vessel.
Hemophilia B
Hemophilia B is treated with Factor IX replacement therapy, given on-demand during bleeding or as regular infusions to prevent bleeding episodes.
TAM
The global Hemophilia B market is projected to grow from USD 1.2 billion in 2022 to USD 2.3 billion by 2029, at a CAGR of 9%, driven by advancements in gene therapies and improved treatment options.
Factor X
Read more
Factor X (also known as Stuart-Prower factor) is a crucial protein in the blood coagulation cascade that helps form blood clots. It is produced in the liver and is activated by Factor IXa (in the presence of calcium ions) to become Factor Xa.
Congenital deficiency
To treat congenital Factor X deficiency, patients receive Factor X replacement therapy through infusions of clotting factor concentrates to prevent or control bleeding.
TAM
The global market for coagulation factor deficiencies, including Factor X deficiency, is expected to grow from USD 6.8 billion in 2023 to USD 12.1 billion by 2031, at a CAGR of 7.3%, driven by treatment advancements and rising awareness.
Factor XIII
Read more
Factor XIII is a clotting factor that plays a critical role in stabilizing blood clots. It helps form cross-links between fibrin molecules, strengthening and stabilizing the clot to prevent excessive bleeding.
Congenital deficiency
To treat congenital Factor XIII deficiency, patients receive Factor XIII concentrates to replace the missing clotting factor and prevent bleeding episodes.
TAM
The global market for Factor XIII deficiency treatment is projected to experience steady growth, valued at USD 228 million in 2024, with an estimated compound annual growth rate (CAGR) of 5.8% from 2024 to 2034, reaching USD 400.7 million by 2034.
PCC complex
Read more
Prothrombin Complex Concentrate (PCC) is a blood product that contains clotting factors, particularly Factor II (prothrombin), Factor VII, Factor IX, and Factor X, which are crucial in the blood clotting process.
Anticoagulant overdose, Factor II and Factor X if Factor X not available deficiencies, liver disease
PCC is used to treat anticoagulant overdose and deficiencies of Factor II and Factor X in liver disease, particularly when Factor X is unavailable. PCC provides concentrated Factor II, VII, IX, and X to help restore the coagulation cascade.
TAM
The global market for PCC is expected to expand from USD 1.2 billion in 2023 to approximately USD 2.2 billion by 2033, with a compound annual growth rate (CAGR) of around 6.2%.
Immunoglobulin
Read more
Immunoglobulin (Ig) refers to a class of proteins that function as antibodies, produced by the immune system to fight infections. There are five main types of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, each playing a distinct role in immune response.
Passive prophylaxis, immune deficiency disorders, some types of immune thrombocytopenic purpura, Guillain–Barré syndrome, polyneuropathies
Immunoglobulin therapy treats immune deficiency disorders, ITP, Guillain–Barré syndrome, and polyneuropathies by boosting immunity. It also provides passive prophylaxis, offering immediate infection protection to individuals with weakened immune systems using pooled antibodies from healthy donors.
TAM
The global immunoglobulin market was valued at approximately USD 13.59 billion in 2022 and is expected to reach USD 21.58 billion by 2026, growing at a compound annual growth rate (CAGR) of 8.01%
Antithrombin III
Read more
Antithrombin III (ATIII) is a naturally occurring protein in the blood that plays a crucial role in regulating blood clotting. It acts as an inhibitor of several clotting factors, including thrombin and Factor Xa, thus helping to prevent excessive clotting (thrombosis).
Congenital deficiency, disseminated intravascular coagulation
Antithrombin III is used to treat congenital deficiency and manage disseminated intravascular coagulation (DIC) by supplementing low levels of the protein to prevent clotting issues and restore coagulation balance.
TAM
The global market is experiencing steady growth. In 2023, the market was valued at approximately USD 502 million and is projected to reach around USD 735 million by 2030, with a compound annual growth rate (CAGR) of 4.8%.
Fibrinogen
Read more
Fibrinogen is a soluble protein produced by the liver that plays a key role in blood clotting. When tissue damage occurs, fibrinogen is converted by the enzyme thrombin into fibrin, forming a mesh that helps stop bleeding by stabilizing blood clots.
Congenital deficiency, massive haemorrhage
Fibrinogen is used to treat congenital fibrinogen deficiency and massive hemorrhage by restoring clotting. Fibrinogen concentrate or cryoprecipitate raises fibrinogen levels to control bleeding, especially in surgery or trauma.
TAM
The fibrinogen market, driven by congenital deficiency and emergency application is projected to grow at a CAGR of 6.1%, reaching approximately USD 5.9 billion by 2033. Demand increases are expected in regions like North America and Asia-Pacific due to advanced healthcare and medical tourism.
C1 inhibitor
Read more
C1 inhibitors are proteins that regulate the complement system, an essential part of the immune response, to prevent excessive inflammation. They are especially important in managing hereditary angioedema (HAE), a rare genetic disorder marked by severe swelling.
Hereditary angioedema
C1 inhibitors treat hereditary angioedema (HAE) by replenishing the missing or faulty protein, helping prevent swelling attacks and regulating inflammation.
TAM
The global hereditary angioedema (HAE) therapeutics market, including C1 esterase inhibitors, is expected to reach USD 5.5 billion by 2027, growing at a CAGR of 8.2%. This growth is driven by increased awareness, better treatments, and rising diagnoses, particularly in North America and Europe.
Albumin
Read more
Albumin is a vital protein in the blood, produced by the liver, and plays a crucial role in maintaining oncotic pressure and fluid balance in the body. It helps in transporting hormones, vitamins, and drugs, and is also involved in regulating the blood’s pH.
Hypoalbuminemia, ascites, restoring of blood volume in trauma, burns and surgery patients
Albumin is used to treat hypoalbuminemia, ascites, and restore blood volume in trauma, burns, or surgery patients. It helps maintain fluid balance and blood pressure in critical conditions.
TAM
The global albumin market, valued at USD 6.74 billion in 2024, is projected to grow to USD 11.02 billion by 2033, with a CAGR of 5.62%. This growth is fueled by rising demand for treatments for hypoalbuminemia, liver cirrhosis, trauma, and burns.
